oxdralazine

RN & N1 given for parent; oxdralazine, L-6150, & DL 150 IT are for di-HCl; hydrazinopyridazine is used as shortened name for this cpd; named as 3-hydrazino- or 6-hydrazino- depending on which numbering system used; RN given refers to parent cpd; structure in Negwer, 5th ed, #862

Also Known As:

3-(bis(2-hydroxyethyl)amino)-6-hydrazinopyridazine; 3-hydrazino-6-(N,N-bis(2-hydroxyethyl)amino)pyridazine dihydrochloride; DL 150 IT; L 6150; L-6150; hydrazinopyridazine; oxdralazine dihydrochloride; 6-(bis(2-hydroxyethyl)amino)-3(2H)-pyridazinone, hydrazone

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Hypertension (High Blood Pressure) 04/01/1983 - "A crossover trial of oxdralazine in hypertension." 06/01/1980 - "Oxdralazine, a pyridazine shown to induce prolonged arteriolar dilation in animals, was given orally in doses of 15 to 30 mg to 7 subjects with hypertension. " 06/01/1980 - "Hemodynamic effects of oxdralazine and hydralazine in hypertension." 11/01/1975 - "[Activity of a new derivative of 3-hydrazinopyridazine: ISF 2123 in patients with hypertension. " 06/01/1978 - "We determined antihypertensive effect of L 6150 for 11 weeks in spontaneously hypertension due to clipping (CLIP). "
2.	Essential Hypertension 08/01/1981 - "Thirty-one patients with moderate and severe essential hypertension completed a comparative study of oxdralazine and dihydralazine. " 08/01/1981 - "Comparative study of oxdralazine and dihydralazine in essential hypertension." 12/01/1980 - "1. The antihypertensive effect of the new drug, SKF 92 657, a hydrazinopyridazine derivative, possessing both beta-adrenoreceptor-blocking and vasodilating properties, was investigated in essential hypertension. " 01/01/1976 - "The acute systemic and coronary haemodynamic effects of a new hypotensive drug L 6150 (3-hydrazino-6-[N,N-bis(2-hydroxyethyl)amino]pyridazine) have been studied in six patients with renal or essential hypertension. " 01/01/1983 - "After an initial placebo period of four weeks 24 patients with primary hypertension were treated with prizidilol, a hydrazinopyridazine derivative with combined vasodilator and non-selective beta-adrenoceptor blocking actions, for a dose titration period of 14 weeks. "

Related Drugs and Biologics

1.	Antihypertensive Agents (Antihypertensives)
2.	pyridazine
3.	Vasodilator Agents (Vasodilators)
4.	Adrenergic Receptors (Adrenergic Receptor)
5.	Hydralazine (Apresoline)
6.	Dihydralazine
7.	prizidilol
8.	propildazine

Related Therapies and Procedures

1.	Surgical Instruments (Clip)